Press Release - October 22, 2024
22 October 2024
ATANIS Biotech, a company specializing in advanced allergy diagnostics, has successfully completed an oversubscribed funding round, led by Spectrum Moonshot Fund and supported by experienced investors in the allergy field.
The funds will be used to ramp up marketing efforts for ATANIS’s cutting-edge FAST-PASE® allergy test in the U.S. and Europe. This innovative diagnostic tool is designed to address the growing need for safer and more accurate functional allergy testing solutions.
In addition, ATANIS welcomed Jascha Forster to its board of directors. His expertise in financing and scaling high-growth companies will be invaluable as ATANIS continues its expansion.
